What is Translate Bio Cash-to-Debt?
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Translate Bio's cash to debt ratio for the quarter that ended in Jun. 2021 was 11.53.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Translate Bio could pay off its debt using the cash in hand for the quarter that ended in Jun. 2021.
The historical rank and industry rank for Translate Bio's Cash-to-Debt or its related term are showing as below:
TBIO'
s Cash-to-Debt Range Over the Past 10 Years
Min: 9.49 Med: 15.74 Max: No Debt
Current: 11.53
During the past 5 years, Translate Bio's highest Cash to Debt Ratio was No Debt. The lowest was 9.49. And the median was 15.74.
Translate Bio Cash-to-Debt Historical Data
The historical data trend for Translate Bio's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Translate Bio Cash-to-Debt Chart
|
Translate Bio Annual Data
|
|
Trend |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
| Cash-to-Debt |
|
No Debt |
No Debt |
No Debt |
14.96 |
10.43 |
|
Translate Bio Quarterly Data
|
|
Dec16 |
Mar17 |
Jun17 |
Sep17 |
Dec17 |
Mar18 |
Jun18 |
Sep18 |
Dec18 |
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
| Cash-to-Debt |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
23.62 |
10.30 |
10.43 |
10.79 |
11.53 |
Competitive Comparison of Translate Bio's Cash-to-Debt
For the Biotechnology subindustry, Translate Bio's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Translate Bio's Cash-to-Debt Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Translate Bio's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Translate Bio's Cash-to-Debt falls into.
Translate Bio Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Translate Bio's Cash to Debt Ratio for the fiscal year that ended in Dec. 2020 is calculated as:
Translate Bio's Cash to Debt Ratio for the quarter that ended in Jun. 2021 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Translate Bio (Translate Bio) Business Description
Traded in Other Exchanges
N/A
Address
29 Hartwell Avenue, Lexington, MA, USA, 02421
Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, for the treatment of cystic fibrosis (CF) and MRT5201, for the treatment of ornithine transcarbamylase (OTC) deficiency.
Executives
| Jean Francois Formela |
director |
C/O ATLAS VENTURE, 890 WINTER STREET, WALTHAM MA 02451 |
| Renaud Ronald C Jr |
director, officer: Chief Executive Officer, other: President |
C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02109 |
| Paul D. Burgess |
officer: Chief Operating Officer, CLO, other: Secretary |
C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421 |
| Owen Hughes |
director |
C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139 |
| Shire Human Genetic Therapies, Inc. |
10 percent owner |
300 SHIRE WAY LEXINGTON MA 02421 |
| Takeda Pharmaceutical Co Ltd |
10 percent owner |
1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668 |
| Baupost Group Gp, L.l.c. |
10 percent owner |
10 ST. JAMES AVENUE, SUITE 1700, BOSTON MA 02116 |
| Seth A Klarman |
10 percent owner |
10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116 |
| Baupost Group Llc/ma |
10 percent owner |
10 ST JAMES AVE, SUITE 1700, BOSTON MA 02116 |
| George Demetri |
director |
BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142 |
| Daniella Beckman |
director |
C/O IDENIX PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG. 1400, CAMBRIDGE MA 02139 |
| Robert M Plenge |
director |
C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421 |
| Daniel Lynch |
director |
|
| Robert J. Meyer |
director |
2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713 |
| Ann Barbier |
officer: Chief Medical Officer |
255 STATE STREET, C/O PIERIS PHARMACEUTICALS,INC., BOSTON MA 02109 |
Translate Bio (Translate Bio) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TBIO has been successfully added to your